RxDoctor Payments Data

Charles Kent, MD

Ophthalmology · Pittsburgh, PANPI 1841253168

Payments from drug & device makers

$3,115in general payments, 2019–2025

Across 45 payments — averaging $69.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Regeneron Healthcare Solutions, Inc.$295
  • Alcon$293
  • Novartis$77
  • Oyster Point Pharma, Inc.$52
  • Aerie Pharmaceuticals, Inc.$35
  • plus $184 from 9 others

What the payments were for

  • Speaking & faculty fees$2,10067%
  • Food & beverage$1,01533%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,115 in reported general payments places this provider in the 65th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$296,715
Medicare patients
681
Services billed
4,387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine114$105,946
XiidraLifitegrast92$78,122
Cyclosporine119$78,109
Prednisolone Acetate410$18,561
Restasis MultidoseCyclosporine11$10,621
MieboPerfluorohexyloctane/Pf11$8,050
MoxifloxacinMoxifloxacin Hcl332$7,301
Ketorolac Tromethamine348$4,491
Timolol Maleate50$2,326
ErythromycinErythromycin Base225$2,192
Travoprost15$1,944
Latanoprost136$1,919
Tobramycin-DexamethasoneTobramycin/Dexamethasone41$1,333
Brimonidine Tartrate53$755
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha49$563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Restasis Multidose$18$116,567125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →